Tuesday, March 17, 2026

The Princess Without a Title: Kim Ju-ae Trails in North Korea’s Succession Race

Former lawmaker Tae Yong-ho explains Kim Ju-ae's successor training, noting she hasn't been officially designated as heir yet.

North Korea Drone Incident: What Does South Korea’s Government Response Mean for Tensions?

The South Korean government will investigate North Korea's drone incursion allegations, emphasizing its intent to ease tensions.

President Yoon Plans Major Public Briefing on Key Reforms

South Korean President Yoon Suk Yeol is considering directly explaining his plans on key national agendas, including ...

Jung Eun Kim

Author's Latest

Big Pharma Braces for $300 Billion Loss as Blockbuster Drug Patents Expire

Global pharma faces $300B losses from patent expirations, prompting a shift to multi-indication drugs and innovative therapies.

New Obesity Drug Shows Big Promise — and It’s Not from Eli Lilly or Novo

Metsera leads emerging obesity treatments with promising drug MET-233i, showing significant weight loss in trials, amid rising competition.

BIO USA 2025: Korea’s Pavilion Grows, Deals Multiply, and New Biotech Faces Emerge

BIO USA 2025 showcased South Korea's biotech presence, with significant participation from firms like Samsung Biologics and Lotte Biologics.

Samsung Launches New Mini-Organ Tech to Speed Up Cancer Drug Testing

Samsung Biologics launches Samsung Organoids for drug screening, focusing on anticancer candidates to enhance precision and reduce costs.

Cancer Gone for 3 Years? This New Drug Is Making It Happen

AbbVie's Epkinly shows 96% long-term complete remission in R/R large B-cell lymphoma patients, highlighting its effectiveness as a therapy.

J&J Aims to Treat Cancer Before It Starts Showing Symptoms

Johnson & Johnson leads in multiple myeloma treatment, pioneering early intervention for high-risk patients with a new subcutaneous formulation.

Opdivo Wins EU Approval in Big Step for Early Lung Cancer Treatment

Opdivo gains EU approval for perioperative therapy in NSCLC, enhancing competition with Keytruda and marking a treatment paradigm shift.

Ozempic Maker Swaps CEO, Bets $2.2B on New Obesity Drug Fight

Novo Nordisk's leadership change aims to reclaim its obesity treatment market share amid competition from Eli Lilly's Mounjaro.

New Study: Mounjaro Helps Users Drop Over 50 Pounds

Eli Lilly's Mounjaro leads U.S. obesity drug market, outperforming semaglutide in weight loss efficacy and safety.

Novo Nordisk and Lilly Block Generics, Tighten Grip on $125B GLP-1 Market

Novo Nordisk and Eli Lilly secure court victories against generics, maintaining dominance in the GLP-1 treatment market amid rising demand.

Novo Nordisk Pushes for First Oral Obesity Drug Approval

Novo Nordisk seeks FDA approval for oral Wegovy, potentially the first oral obesity treatment, amid competition with Eli Lilly.

Eli Lilly’s Oral GLP-1 Shows 7.9% Weight Loss in Type 2 Diabetes Trial

Eli Lilly's orforglipron shows promise in Phase 3 trials for diabetes and obesity, offering an oral alternative to injectables.

President Yoon Announces Historic Oil Discovery in South Korea

After President Yoon announced the "potential for a massive amount of oil and natural gas reserves off Pohang," oil stocks have risen.

Top News

- Our Sponsors Ad -

Follow us

Cars

Tech

future

health

© Copyright by News1. All Rights Reserved.